Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02310750 · ClinicalTrials.gov registry record · Phase 1

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

A Phase 1 study of Plaque Psoriasis, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
96
Enrollment target
1
Study location

NCT02310750: Completed Phase 1 study of Plaque Psoriasis, sponsored by Pfizer.

NCT02310750 is a Phase 1 study of Plaque Psoriasis that has completed, run by Pfizer. The registered enrollment target is 96 participants, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02310750, a Phase 1 study of Plaque Psoriasis, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
96 participants
Enrollment target
1
Study location

Study Summary

The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).

Conditions Studied

Plaque Psoriasis

Interventions

  • OTHER Placebo
  • DRUG PF-06700841 oral solution/suspension
  • DRUG PF-06700841 tablet

Study Locations (1)

California

  • Anaheim Clinical Trials, LLC - Anaheim

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2014-11
Est. Completion 2016-02
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT02310750 record still lists

NCT02310750 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02310750 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02310750 about?

NCT02310750 is a clinical study titled "A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation". The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic propert...

What is the current status of trial NCT02310750?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2014-11. Estimated completion is 2016-02.

What conditions does trial NCT02310750 study?

This clinical trial studies the following conditions: Plaque Psoriasis.

What interventions are being tested in trial NCT02310750?

The interventions under investigation include: Placebo (OTHER), PF-06700841 oral solution/suspension (DRUG), PF-06700841 tablet (DRUG).

Who is sponsoring clinical trial NCT02310750?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02310750 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Plaque Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02310750's enrollment target sits among peer trials

96 30th of 45 higher than 16 of 45 other Plaque Psoriasis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02310750, the US trial registry maintained by the National Library of Medicine. NCT02310750 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.